scholarly journals Tucatinib (Tukysa)

2022 ◽  
Vol 2 (1) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Brain Metastases ◽  
Drug Class ◽  
Locally Advanced ◽  
Clinical Effectiveness ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Clinician Perspectives ◽  
Positive Breast Cancer

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses tucatinib (Tukysa), 50 mg and 150 mg tablets, orally. Tucatinib in combination with trastuzumab and capecitabine for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and T-DM1 separately or in combination.

scholarly journals 4CPS-124 Safety and effectiveness of trastuzumab emtansin in locally advanced or metastatic HER2 positive breast cancer

2019 ◽  
Author(s):  
M Mejias Trueba ◽  
R Jiménez Galán ◽  
M Muñoz Burgos ◽  
AB Guisado Gil ◽  
MD Vega Coca ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Locally Advanced ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer

2021 ◽  
pp. 68-74
Author(s):  
E. V. Lubennikova ◽  
Ya. V. Vishnevskaya
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Neoadjuvant Therapy ◽  
Locally Advanced ◽  
Residual Tumor ◽  
Long Term Results ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

The widespread introduction of anti-HER2 agents has changed the natural course of Her2-positive breast cancer. The use of trastuzumab, and later dual anti-HER2 blockade with pertuzumab, in neoadjuvant regimens significantly increased the chances of complete cure. However, among patients with early and locally advanced forms of Her2-positive cancer, there is a cohort with an extremely unfavorable prognosis – tumors that have not achieved complete pathomorphological regression after neoadjuvant chemotherapy.The presence of a residual tumor in Her2-positive breast cancer has long been only a prognostically unfavorable factor without the potential to influence disease outcome. The results of the international phase III study KATHERINE, which demonstrated the high efficacy of post-adjuvant therapy with trastuzumab emtansine (T-DM1) in this patient cohort, have established a new standard of care. Due to T-DM1 adjuvant therapy, the possibility to significantly improve long-term results determined the predictive characteristics of the morphological response to the choice of treatment tactics, which became an important argument in favor of neoadjuvant therapy in patients with not only locally advanced but also primarily resectable Her2-positive breast cancer, followed by personalization of therapy.This article presents our own experience with post-neoadjuvant therapy with trastuzumab emtansine in a young patient with a residual tumor. The data of the main studies in early Her2-positive breast cancer are summarized.

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

2007 ◽  
Vol 85 (3) ◽  
pp. 311-317 ◽  
Author(s):  
Rupert Bartsch ◽  
Andrea Rottenfusser ◽  
Catharina Wenzel ◽  
Karin Dieckmann ◽  
Ursula Pluschnig ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Brain Metastases ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Repeated courses of radiation treatment in an HER2‐positive breast cancer patient with diffuse brain metastases: A case report

2020 ◽  
Vol 26 (7) ◽  
pp. 1370-1371
Author(s):  
Sonia Silipigni ◽  
Edy Ippolito ◽  
Paolo Matteucci ◽  
Bianca Santo ◽  
Emma Gangemi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Brain Metastases ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Radiation Treatment ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Diffuse Brain ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document